Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
28 /100
MEDIUM RISK
Score updated Aug 28, 2026

SNDX — Syndax Pharmaceuticals, Inc. Dilution Risk Tracker

Track SNDX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SNDX — Get alerts when the score changes →

As of August 28, 2026, Syndax Pharmaceuticals, Inc. (SNDX) has a DilutionWatch DilutionScore of 28/100, rated MEDIUM dilution risk. Syndax Pharmaceuticals, Inc. has a market capitalization of $1.74B, 89.30M shares outstanding, 246 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
10
📊 Float Risk
20
⚠️ Warrant Exposure
40
🔄 Convertible Debt
35

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 7%
🔁 Convertible Conversion model 15%
• Convertible debt present: 14.1% potential dilution
🔔 Track SNDX — Get forecast alerts →

Market Data

Market Cap$1.74B
Shares Outstanding89.30M
Float79.03M
Cash$547.86M
Debt$344.03M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 12.6% shares (2026Q1 vs prior)
246 institutional holders · 120.03M shares
#1 GOLDMAN SACHS GROUP INC 10.69M shares
#2 BlackRock, Inc. 8.25M shares
#3 Kynam Capital Management, LP 8.05M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest22.67M
Days to Cover18.6
% of Float28.7%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-06-30
Full SEC filing analysis available with free account

Recent News

No recent news

Factual SNDX Dilution Snapshot

Syndax Pharmaceuticals, Inc. (SNDX) has a DilutionScore of 28/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track SNDX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SNDX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for SNDX
SNDX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.